The effect of subcutaneous and sublingual birch pollen immunotherapy on birch pollen–related food allergy: a systematic review

Autor: E. J. J. Kallen, P. M. J. Welsing, J. M. Löwik, R. Van Ree, A. C. Knulst, T. M. Le

Publikováno v: Frontiers in Allergy, Vol 5 (2024)

BackgroundBirch pollen–related food allergy (BPFA) is the most common type of food allergy in birch-endemic areas such as Western and Central Europe. Currently, there is no treatment available for BPFA. Due to the cross-reactivity between birch pol

Externí odkaz: https://doaj.org/article/83b58a88795348a68428fd68585e534b

Adherence During Early Allergen Immunotherapy and Strategies to Motivate and Support Patients

Autor: Natalija Novak, Timo Buhl, Oliver Pfaar

Publikováno v: European Medical Journal, Vol 3, Iss 3, Pp 21-29 (2018)

Allergic rhinitis is one of the most common chronic inflammatory conditions, affecting up to 30% of people in Europe. Allergen immunotherapy (AIT) is the only treatment for allergic rhinitis and asthma that has a disease-modifying effect, and it is r

Externí odkaz: https://doaj.org/article/cc03fc1f4e7a4840869839bf00992a29

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: Results from the REACT study, a retrospective cohort study

Autor: Celeste Porsbjerg, Benedikt Fritzsching, Marco Contoli, Mercedes Romano Rodriguez, Lisa Elliott, Sarah Buchs, Julie Rask Larsen, Nick Freemantle

Publikováno v: The Lancet Regional Health-Europe
Fritzsching, B, Contoli, M, Porsbjerg, C, Buchs, S, Larsen, J R, Elliott, L, Rodriguez, M R & Freemantle, N 2022, ' Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma : Results from the REACT study, a retrospective cohort study. ', The Lancet Regional Health-Europe, vol. 13, 100275 . https://doi.org/10.1016/j.lanepe.2021.100275
The Lancet Regional Health. Europe, Vol 13, Iss, Pp 100275-(2022)

Background: Allergen immunotherapy (AIT) is the only causal treatment for respiratory allergy. Long-term real-life effectiveness of AIT remains to be demonstrated beyond the evidence from randomised controlled trials (RCTs). Methods: REACT (Real worl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ffc8f543ea1923373f6920b4db91b89
https://doi.org/10.1016/j.lanepe.2021.100275

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.